INVESTOR CENTRE

ASX Announcements

Notification of cessation of securities - EVE

Notice of Annual General Meeting/Proxy Form

Quarterly Activities/Appendix 5B Cash Flow Report

Annual Report to shareholders

Appendix 4G and Corporate Governance Statement

Date of AGM and Closing Date for Director Nominations

Sale of Robyndale Property (Amended)

Appendix 4E - Results for Announcement to the Market

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Details of Auditor Appointment/Resignation

Sale of Jendale Property

Appendix 4D and Half Year Report

Quarterly Activities/Appendix 4C Cash Flow Report

Farm Sale and Funding Update

New Constitution

Change of Director's Interest Notice

Notification of cessation of securities - EVE

Quarterly Activities/Appendix 4C Cash Flow Report

Notice of Annual General Meeting/Proxy Form

Letter to Shareholders - AGM Notice

Annual Report to shareholders

Appendix 4G and Corporate Governance Statement

Date of AGM and Closing Date for Director Nominations

Appendix 4E - Results for Announcement to the Market

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Director Resignation

Appendix 4D and Half Year Report

Appendix 4C - December Quarter 2022

Sale of Investment in Omni Innovation

Results of Meeting

Appendix 4C - September Quarter 2022

Notice of Annual General Meeting/Proxy Form

Letter to Shareholders - AGM

Annual Report to shareholders

Appendix 4G and Corporate Governance Statement

Director Resignation

Date of AGM and Closing Date for Director Nominations

Application for quotation of securities - EVE

Allotment of Shortfall Shares

Sale of Investment in Omni Innovation

Notification of cessation of securities - EVE

Appendix 4E and Preliminary Final Report

Appendix 4C - June Quarter 2022

Director Resignation and Appendix 3Z

Change of Director's Interest Notice x 3

Becoming a substantial holder

Application for quotation of securities - EVE

Completion of Rights Offer

Reminder of Closing Date for Non-Renounceable Rights Offer

Appointment of Director - Rodney Hannington

Initial Director's Interest Notice

Cleansing Notice

Rights Issue Offer Document

Despatch of Offer Document

Proposed issue of securities - EVE

Non-Renounceable Rights Offer

Cleansing Notice

Letter to Optionholders

Change of Share Registry

Notification regarding unquoted securities - EVE

Appendix 4C - March Quarter 2022

Results of Meeting

Update - Proposed issue of securities - EVE

Notice of General Meeting/Proxy Form

Letter to Shareholders - Notice of General Meeting

Application for quotation of securities - EVE

Cleansing Notice

Appendix 4D and Half Year Report

$1.4m Share Placement

Update - Proposed issue of securities - EVE

Update - Proposed issue of securities - EVE

Appendix 4C - December Quarter 2021

Meluka Australia - Half Year Update

Change of Director's Interest Notice x 3

Notification of cessation of securities - EVE

Alliance Agreement - Australian Sales Force

Alliance Agreement - Additional Information

Change of Company Name

Change of Director's Interest Notice

2021 AGM Presentation

Results of Meeting

Appendix 4C - September Quarter 2021

Letter to Shareholders - Notice of Annual General Meeting

Notice of Annual General Meeting/Proxy Form

Meluka’s Sales Performance Drives New Probiotic Product Range in Collaboration with Probiotics Australia

Omni Innovation - New Partner Launches Product

Notice of AGM Date

2021 Annual Report

Appendix 4G and Corporate Governance Statement

Appendix 4E

Appendix 4C - June Quarter 2021 - Amended

Appendix 4C - June Quarter 2021

Company Update

US Distribution - First Whole Foods Order Received

Appendix 4C - March Quarter 2021

Director Appointment / Retirement

Investor Presentation

Company Update

Appendix 4D and Half Year Report

Appendix 4C - December Quarter 2020

Omni Innovation Enters Licencing Agreement

Acceptance into Major USA Grocery Chain - Whole Foods Market

Change of Director's Interest Notice

AGM Presentation

Results of Meeting

Appendix 3G

Company Update

Appendix 3G

Appendix 2A

Notice of Annual General Meeting / Proxy Form

Letter to Shareholders - Notice of Annual General Meeting

Appendix 4C - September Quarter 2020

Appendix 2A

Appendix 2A

Change of Director's Interest Notice

Closing Date for Director Nominations

Appendix 2A

Appendix 4E

2020 Annual Report

Appendix 4G and Corporate Governance Statement

China Sales Update - First Tea Tree Honey Order

EVE Investor Webinar

China Sales Update

Investor Presentation

Appendix 4C - June Quarter 2020

Retirement of Non-Executive Director and Appendix 3Z

China Sales and Manufacturing Update

Change of Director's Interest Notice x 3

Company Update

Change of Director's Interest Notice

Appendix 4C - March Quarter 2020

Market Update - COVID-19 and operations

Appendix 2A

Appendix 4D and Half Year Report

Quarterly Review

Director Appointment

Investor Presentation

Ceasing to be a substantial holder

$6.9m Tranche 2 Placement Completed

Tranche 2 Placement Completion Update

Company Update

Update on Second Subscription Placement

Change in substantial holding

Completion of First Subscription

Appendix 3B

Prospectus

Initial Director's Interest Notice

Tranche 1 Placement Funds Received

Adoption of Revised Constitution

Voluntary Suspension

Trading Halt

Results of Annual General Meeting

Quarterly Review

Notice of Annual General Meeting / Proxy Form

Reinstatement to Official Quotation

$9.3m Strategic Placement

Notice under s708A(5) of the Corporations Act

Appendix 3B

Change of Director's Interest Notice x 4

Suspension from Official Quotation

Trading Halt

Appendix 4G and Corporate Governance Statement

Annual Report to Shareholders

Appendix 4E Preliminary Final Report

Company Update

Notice of General Meeting and Proxy Form

Capital Raising Update

Quarterly Review

Appendix 3B

EVE Placement Raises $750k

THC Global Agreement Update

Company Update

Meluka Honey Market Update

THC Global Agreement Update

Appendix 3B

Response to Appendix 4C Query

THC Global Agreement Update

Quarterly Review

Appendix 3B

Placement

Meluka Honey US Update

Meluka Honey Appoints OpenDNA (Revised)

Meluka Honey Appoints OpenDNA to Support Chinese Market Entry

Singapore and Hong Kong Company Roadshow Presentation

Meluka Honey Secures Distribution for Northern NSW & South East Qld

Appendix 4D and Half Year Report

EVE to Acquire Remaining 50% of Meluka Health

Appendix 3B

Response to ASX Appendix 4C Query

Quarterly Review

Appendix 3B

Presentation

Appendix 3B

Results of Annual General Meeting

Appendix 3Y

Meluka Honey Secures Distribution for NSW & ACT

Change of Director's Interest Notice

Southern Cross University Media Release

Meluka Honey Combines Anti-Microbial & Anti-Oxidant Activity

Quarterly Review

Notice of Annual General Meeting and Proxy Form

Appendix 4G and Corporate Governance Statement

Annual Report to Shareholders

Notice of change of interests of substantial holder

Appendix 4E and Full Year Statutory Accounts

Presentation

Omni Innovation - Update by Eagle Health

Appendix 3B

Completion of Jenbrook Transaction

Prospectus

Results of General Meeting

Quarterly Review

Completion of THC Agreements

Notice of General Meeting/Proxy Form

Update by Eagle Health on Chinese Market

Update on THC Agreements

EVE to Acquire Leading Australian Organic Tea Tree Oil Producer

Trading Halt

Eagle Plans to Significantly Expand China Distribution

Corporate Update

Meluka Health and THC Execute Term Sheet

Quarterly Review

First Quarter China Sales Progress

Net Tangible Asset Backing

Change of Director's Interest Notice x 4

Appendix 3B

Allotment of Rights Issue Shortfall

Net Tangible Asset Backing

Investor Presentation

Completion of Rights Issue

Half Yearly Report and Accounts

Meluka Honey Consumer Products Launch at US Natural Products Expo

Rights Issue Offer Document

Eagle Commences Marketing and Sales in China

Net Tangible Asset Backing

Letter to Shareholders

Omni Innovation Update by Eagle on Chinese Rollout

Pro-Rata Non-Renounceable Rights Offer

Letter to Optionholders

Appendix 3B and Section 708AA(2)(f) Notice

Appendix 3B

Appendix 3B

Capital Raising Update

Prospectus

Oversubscribed Placement and Rights Issue to Raise up to $6.3m

Change to Board Roles

Appendix 3B

Quarterly Review

Trading Halt

Appendix 3B

Change of Director's Interest Notice x 4

Appendix 3B

Appendix 3B

Net Tangible Asset Backing

Eagle Begins Shipment of Omni Innovation’s Diabetes Product

Appendix 3B

Meluka Health to Develop Honey Water for Chinese Market

Eve Completes 50% Investment in Meluka Health

Change of Director's Interest Notice x 2

Appendix 3B

Response to ASX Price & Volume Query

Appendix 3B

NSW Grant for Honey Research Successful

Change of Director’s Interest Notice

Medic Honey Produces a Hemp Seed Honey

Prospectus

Results of Annual General Meeting

Appendix 3B

Sydney Investor Roadshow Presentation

Net Tangible Asset Backing

Philip Owens Appointed CEO of Omni Innovation

Meluka Honey Branding and Marketing Commences

Supply Agreement with Large Producer of Australian Organic Honey

Meluka Health Appoints Leading Bee And Honey Advisor

Eagle Commences Production of Omni Innovation’s Pre‐Meal Shake

Appendix 4C - Quarterly

Appendix 4G and Corporate Governance Statement

Annual Report to Shareholders

Notice of Annual General Meeting and Proxy Form

Appendix 4C - Quarterly

Appendix 4G and Corporate Governance Statement

Notice of Annual General Meeting/Proxy Form

Annual Report to Shareholders

Replacement Appendix 3B

Initial Director's Interest Notice

Appendix 3B

Prospectus

Net Tangible Asset Backing

$1.2M Capital Raising

Update on Capital Raising

Suspension from Official Quotation

Trading Halt

Omni Innovation Executes Chinese Licence Agreement

Net Tangible Asset Backing

Appendix 4E and Full Year Statutory Accounts

Revised Medical Honey Investment Structure

Omni Innovation Enters Chinese Distribution Agreement with Eagle Health

Net Tangible Asset Backing

Trading Halt

Appendix 4C - Quarterly

Net Tangible Asset Backing

Change of Director's Interest Notice x 3

Appendix 3B

Prospectus

Accelerating Portfolio Progress

Results of General Meeting

Net Tangible Asset Backing

Investor Presentation

Southern Cross University Collaboration with Medic Honey

Notice of General Meeting/Proxy Form

Appointment of Leading Medicinal Cannabis Advisor

Net Tangible Asset Backing

Change of Director's Interest Notice x 3

Replacement Appendix 3B

Change in Substantial Holding

Prospectus

Appendix 3B

EVE Capital Raising Completed

EVE Capital Raising Oversubscribed

Reinstatement to Official Quotation

Eve Invests in Pioneering Cannabis Honey & Tea Tree Oil Co

Appendix 4C - Quarterly

LNK: Change of Perth Address for Shareholder Purposes

Update on Capital Raising

Update on Capital Raising

Net Tangible Asset Backing

Update on Capital Raising

Update on Capital Raising

Voluntary Suspension

Trading Halt

Omni Innovation - US Manufacturer Appointed

Omni Innovation Completes UK Licence Agreement

Net Tangible Asset Backing

Omni Innovation US Update

Omni Innovation - US Patent Notice of Allowance Received

Omni Innovation Update

Half Yearly Report and Accounts

Results of Meeting

Net Tangible Asset Backing

Appendix 4C - Quarterly

Sales Results Exceed Expectations for Faulding GlucoControl

Change of Director's Interest Notice

Notice of General Meeting/Proxy Form

Change in Substantial Holding

Net Tangible Asset Backing

Appendix 3Y

Update on Omni Innovation Investment

RGP: Refresh Invests in Technology Company

Reinstatement to Official Quotation

$1.6m Placement for Omni Innovation Investment

Appendix 3B

Prospectus

Net Tangible Asset Backing

Withdrawal of Entitlement Issue

Suspension from Official Quotation

Trading Halt

Notification of Rights Issue Shortfall

Omni Innovation Market Update

Rights Issue Offer Document

Becoming a Substantial Holder

Results of Meeting

Omni Innovation secures UK Distribution Deal

Letter to Shareholders

Non-Renounceable Rights Offer

Letter to Optionholders

Appendix 3B and Cleansing Notice

Appendix 3B

Net Tangible Asset Backing

Placement to Chinese Pharmaceutical and Investment Group

Reinstatement to Official Quotation

Voluntary Suspension

Trading Halt

Appendix 4C - Quarterly

Appendix 4C - Quarterly

Annual Report to Shareholders

Notice of Annual General Meeting/Proxy Form

Appendix 4G and Corporate Governance Statement

Net Tangible Asset Backing

EVE Investments Webcast on Omniblend Innovation

Extension of Omniblend Innovation Tranche 2 Settlement

New Study- GlucoControl Improves Long-Term Glycaemic Control

Update on Omniblend Innovation

Net Tangible Asset Backing

Appendix 4E and Full Year Statutory Accounts

Omniblend Innovation Enters into US Representation Deal

Net Tangible Asset Backing

Appendix 4C - Quarterly

Net Tangible Asset Backing

Omniblend Innovation Appoints Director of Sales & Marketing

GlucoControl for type 2 diabetes named Product of the Month

GlucoControl Momentum

Net Tangible Asset Backing

Results of Meeting

Appendix 3B and Change of Director's Interest Notice x 3

Net Tangible Asset Backing

Exclusive Engagement Signed with OHC for Scandinavia

GlucoControl Pre-Meal Drink Launched

Appendix 3B

Notice of General Meeting/Proxy Form

Appendix 4C - Quarterly

Omniblend Innovation Transaction Completed

Net Tangible Asset Backing

Change in Substantial Holding

Extension of Omniblend Innovation Tranche 2 Settlement

Med-Tech Executive Joins EVE Board

Completion of $1.85M Non-Renounceable Rights Issue

Net Tangible Asset Backing

Half Yearly Report and Accounts

GlucoControl Product Manufacturing Commences

Letter to Shareholders

Appendix 3B

Letter to Optionholders

Fully Underwritten Rights Issue

Prospectus

Net Tangible Asset Backing

Investor Presentation - Omniblend Innovation Acquisition

Shareholder Update

Appendix 4C - Quarterly

Net Tangible Asset Backing

Change in Substantial Holding

Appendix 3B

Change of Director's Interest Notice x 2

Additional Information under Listing Rule 4.10.20

EVE Investments makes first medical technology investment

Trading Halt

Net Tangible Asset Backing

Appendix 3B

Change of Company Name

Results of Meeting

Net Tangible Asset Backing

Appendix 4C - Quarterly

Notice of Annual General Meeting/Proxy Form

Prospectus

Annual Report to shareholders

Appendix 4G and Corporate Governance Statement

Net Tangible Asset Backing

Appendix 3B and Change of Director's Interest Notice x 3

Net Tangible Asset Backing

Change to AUD Presentation Currency

Appendix 4E and Full Year Statutory Accounts

Net Tangible Asset Backing

Appendix 4C - Quarterly

Net Tangible Asset Backing

Change in Substantial Holding

Change of Director's Interest Notice x 3

Placement

Trading Halt

Company Update

Net Tangible Asset Backing

Appendix 3B

Net Tangible Asset Backing

Appendix 4C - Quarterly

Net Tangible Asset Backing

Change in substantial holding

Appendix 3B

Change of Director's Interest Notice x 3

Net Tangible Asset Backing

Half Yearly Report and Accounts

Company Update

Net Tangible Asset Backing

Appendix 4C - Quarterly

Change of Director's Interest Notice x 3

Net Tangible Asset Backing

Appendix 3B